Jim Wassil, who serves as the Chief Operating Officer for Vaxcyte, Inc. (NASDAQ: PCVX), completed a divestment of company equity on July 1, 2026. The transaction involved the sale of 2,250 shares of common stock, resulting in a total proceeds value of $126,736. These shares were liquidated across multiple transactions during the trading day, with execution prices fluctuating between $55.60 and $57.82 per share. The sale activity was facilitated under a Rule 10b5-1 trading plan, which Wassil established on December 9, 2025.
On the identical date, Wassil also engaged in an acquisition of company equity. He exercised stock options to acquire 516 shares of Vaxcyte common stock at a strike price of $5.35 per share, totaling $2,760. The options exercised were confirmed as fully vested and exercisable. Following the completion of these simultaneous sale and purchase activities, Wassil's direct holdings stand at 156,760 shares of common stock. Additionally, he retains 71,148 derivative shares in the form of stock options.
Market data indicates that Vaxcyte shares have appreciated significantly over the trailing twelve-month period, recording a 71% return. Despite this performance, analytical assessments suggest that the current valuation may exceed fair value metrics. The stock closed at $56.93, reflecting a decline of $1.46 or 2.50% during regular trading hours. Subsequent to market close, the shares traded higher in after-hours activity, reaching $58.88, an increase of $1.92 or 3.36%.
Concurrent with executive transactions, Vaxcyte announced structural modifications to its board of directors. Jacks Lee retired from the board effective June 17. Lee has since entered into a consulting agreement with the company to provide advisory services regarding global strategic supply and manufacturing operations. Simultaneously, the board appointed Moncef Slaoui as a Class II director. Slaoui's term is scheduled to extend until the annual meeting of stockholders in 2028. The board has confirmed that Dr. Slaoui meets the independence standards required by Nasdaq listing rules.
In clinical developments, Vaxcyte has dosed the first participant in its Phase 1 study of VAX-A1. This investigational vaccine candidate is designed to prevent Group A Streptococcus infections. The trial population consists of healthy adults aged 18 to 40 years. The company projects the release of topline data from this study in the second half of 2027. These events underscore ongoing adjustments in corporate governance and the progression of clinical research initiatives.